With new variants and waning immunity occurring, especially in elderly and immunocompromised individuals, it is important to understand how to utilize the tools we have to prevent severe disease and death.
Sangivamycin is an unsuccessful anti-cancer drug candidate that has proven to be a potent inhibitor of multiple viruses. The authors of this study hypothesized that this compound would also be active against SARS-CoV-2.
The severe acute respiratory coronavirus 2 (SARS-CoV-2) has caused the ongoing COVID-19 pandemic, infecting more than 206 million people and causing upwards of 4.34 million deaths at the time of writing.
Taking Advantage of Viral Cytopathic Effects to Aid in the Rapid Screening of Effective Viral Therapies
Virology researchers use CPE effects pathogens elicit on the host to study host-pathogen interactions.
The COVID-19 pandemic has increased SARS-CoV-2 research globally resulting in three publicly available vaccines from Moderna, Pfizer (mRNA-based), and Johnson & Johnson (viral vector-based).
Drug repurposing, also known as drug repositioning is a powerful tool for the rapid expansion of available therapy options by identifying new therapeutic uses from pre-existing drugs.
Between preventative vaccines and palliative treatment for the sickest COVID-19 patients lies the realm of existing drugs that could be repurposed for antiviral prophylaxis.
Is Your Lab Using High-throughput Image Cytometry to Expedite Viral Assay Development and Research of SARS-CoV-2?
Fast track vaccine development process by conducting assays in 96- or 384-well plates based on enumeration of foci, plaque or single infected cells.